Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib
Science Signaling · 2025
DOI: 10.1126/scisignal.adt5931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Signaling, 2025. Verfasst von Serena Muratcioglu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Vanderbilt University, Nashville, TN, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Proteins c-abl, Fusion Proteins, bcr-abl, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Chromosomal translocations that fuse ABL1 to BCR or TEL cause human leukemias. In BCR-ABL and TEL-ABL fusion proteins, oligomerization and loss of an autoinhibitory myristoylation site in the SH3 domain of ABL lead to increased ABL tyrosine kinase activity. We assessed the ability of asciminib, an allosteric inhibitor of BCR-ABL that binds to the myristoyl-binding site in the ABL kinase domain, to inhibit these fusion proteins. Although the ABL components of the two fusion proteins have identical sequences, asciminib was much less effective against TEL-ABL than it was against BCR-ABL in cell-growth assays. In contrast, ATP-competitive tyrosine kinase inhibitors, such as imatinib and ponatinib, were equally effective against both fusion proteins. A helix in the ABL kinase domain that closes over bound asciminib was required for the sensitivity of BCR-ABL to the drug but had no effect on that of TEL-ABL, suggesting that the native autoinhibitory mechanism that asciminib engages in BCR-ABL is disrupted in TEL-ABL. Single-molecule microscopy demonstrated that BCR-ABL was mainly dimeric in cells, whereas TEL-ABL formed higher-order oligomers, which promoted trans-autophosphorylation, including of a regulatory phosphorylation site (Tyr 89 ) in the SH3 domain of ABL. Nonphosphorylated TEL-ABL was intrinsically susceptible to inhibition by asciminib, but phosphorylation at Tyr 89 disassembled the autoinhibited conformation of ABL, thereby preventing asciminib from binding. Our results demonstrate that phosphorylation determines whether an ABL fusion protein is sensitive to allosteric inhibition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Vanderbilt University, Nashville, TN, USA.
- Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
- Biophysics Graduate Group, University of California, Berkeley, Berkeley, CA, USA.
- Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA, USA.
- Department of Chemistry, University of California, Berkeley, Berkeley, CA, USA.
- Division of Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
ORCID-Profile: Serena Muratcioglu, Christopher A Eide, Chien-Lun Hung, Kent Gorday, Emily Sumpena, Wenqi Zuo, Jay T Groves, Brian J Druker, John Kuriyan
Förderung
- NIAID NIH HHS
Zitieren
APA
Muratcioglu, S., Eide, C. A., Hung, C. L., Gorday, K., Sumpena, E., Zuo, W., Groves, J. T., Druker, B. J., & Kuriyan, J. (2025). Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Science Signaling. https://doi.org/10.1126/scisignal.adt5931
Vancouver
Muratcioglu S, Eide CA, Hung CL, Gorday K, Sumpena E, Zuo W, et al. Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Science Signaling. 2025. doi:10.1126/scisignal.adt5931
BibTeX
@article{Muratcioglu2025,
author = {Muratcioglu, Serena and Eide, Christopher A and Hung, Chien-Lun and Gorday, Kent and Sumpena, Emily and Zuo, Wenqi and Groves, Jay T and Druker, Brian J and Kuriyan, John},
title = {Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib},
journal = {Science Signaling},
year = {2025},
doi = {10.1126/scisignal.adt5931}
}
EUVIMED